Envista’s Acquisition of Osteogenics Biomedical

Kirkland & Ellis advised Envista Holdings Corporation on the deal.

Envista Holdings Corporation (NYSE: NVST), a global family of more than 30 trusted dental brands, announced its acquisition of Osteogenics Biomedical, a leader in the development of innovative regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world. The transaction is subject to customary regulatory approvals and is expected to close in the third quarter 2022. Terms of the transaction were not disclosed.

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives.

The Kirkland team was led by corporate partners Douglas DiMedio (Picture) and Michael Brueck and associates Oliver Yee and Josh Dulberg, tax partners Benjamin Schreiner and Vivek Ratnam and associate Rhonda Dinkins, and healthcare regulatory partners Chad Ehrenkranz and Lindsay Borgeson and associate Charles Inclan. 

Involved fees earner: Lindsay Borgeson – Kirkland & Ellis; Michael Brueck – Kirkland & Ellis; Douglas DiMedio – Kirkland & Ellis; Rhonda Dinkins – Kirkland & Ellis; Joshua Dulberg – Kirkland & Ellis; Chad Ehrenkranz – Kirkland & Ellis; R. Charles Inclan – Kirkland & Ellis; Vivek Ratnam – Kirkland & Ellis; Benjamin Schreiner – Kirkland & Ellis; Oliver Yee – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: Envista Holdings Corporation;